|Bid||61.03 x 800|
|Ask||66.35 x 1800|
|Day's range||61.31 - 64.50|
|52-week range||61.31 - 101.24|
|Beta (5Y monthly)||1.25|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||123.21|
Every investor in Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) should be aware of the most powerful shareholder groups...
Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.
Participants from the placebo crossover group in Part 2 of Study SRP-9001-102 , scored 2.0 points higher on the mean North Star Ambulatory Assessment (NSAA) 48 weeks after treatment with SRP-9001 compared to pre-specified matched external control cohort ( p value=0.0009)Results continue to reinforce the tolerability profile of SRP-9001 with no new safety signals identified CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision geneti